Collaborative arrangement revenues and expense sharing percentage.

No definition available.

Name:	plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix:	plx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase in gross sales price of shares available for future issuance.

+ References

No definition available.

+ Details

Name:	plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Aggregate value of common shares reserved for future issuance.

+ References

No definition available.

+ Details

Name:	plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the number of global licensing and supply agreements.

+ References

No definition available.

+ Details

Name:	plx_NumberOfGlobalLicensingAndSupplyAgreements
Namespace Prefix:	plx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- References

No definition available.

+ Details

Name:	plx_SignificantAccountingPoliciesLineItems
Namespace Prefix:	plx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

+ Details

Name:	us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Face amount or stated value per share of common stock.

+ References

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

+ Details

Name:	us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_BR
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Oct. 31, 2015	Jun. 30, 2025 USD ($) agreement $ / shares shares	Mar. 17, 2025 USD ($)	Jan. 31, 2025 $ / shares shares	Dec. 31, 2024 $ / shares	Sep. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES
Number of global licensing and supply agreements \| agreement		2
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares		$ 0.001			$ 0.001
Antidilutive securities excluded from computation of earnings (loss) per share, amount \| shares		2,365,709
Sales Agreement
SIGNIFICANT ACCOUNTING POLICIES
Shares remain for sale \| shares				0
Increase in aggregate gross sales price \| $			$ 20.0
Shares remain available, total gross proceeds \| $		$ 15.7
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares				$ 0.001
2024 Notes
SIGNIFICANT ACCOUNTING POLICIES
Interest rate (as a percent)						7.50%
Amended Pfizer Agreement \| Protalix Bio Therapeutics Incorporation \| Brazil
SIGNIFICANT ACCOUNTING POLICIES
Collaborative arrangement revenues and expenses sharing percentage	100.00%